Search

The article focuses on a study which tries to identify the risk factors associated with the infection of multiple antibiotic-resistant Pseudomonas aeruginosa (MARPA) in patients with cystic fibrosis (CF). The fiver-year study revealed that risk factors for MARPA include diabetes, long-term inhaled tobramycin usage, and frequent acute pulmonary exacerbations requiring hospitalization or IV antibiotics.

The article presents a study which aims to examine the effectiveness of Levofloxacin in treating cystic fibrosis (CF) patients. Numerous data revealed that CF levofloxacin pharmacokinetics corrected for body weight are similar to non-CF but the standard levofloxacin dosing is unlikely to produce maximum therapeutic effectiveness. Thus, further levofloxacin CF studies are essential to assess its phlegm concentrations for coping Pseudomonas Aeruginosa pulmonary infections.

Background: The peptide drug Molil901 activates an alternative chloride channel that is present in cystic fibrosis (CF) nasal and airway epithelia. Doing so bypasses the dysfunctional CF transmembrane regulator. Study objective: To determine whether intranasal Moli1901 is safe, tolerable, and will induce chloride transport in healthy volunteers and CF subjects. Design: A single-blind (to the participant), randomized, placebo-controlled, dose-escalation study of intranasal Molil901 was performed in four healthy non-CF participants and four participants with CF. Drug or placebo was administered by intranasal superfusion, and nasal potential difference responses were continuously monitored during sequential dose escalations at 1-min intervals from 0.01 through 10 µmol/L. Results: Neither Molil901 nor placebo were associated with visible changes such as edema, erythema, drainage, secretions, or ulcer formation. No elevations in lactate dehydrogenase, albumin, or cell counts were observed in nasal lavage fluid after administration. No clinically significant changes in FEV[sub 1] or other toxicity parameters occurred. Changes in the nasal potential difference (NPD) induced by chloride-free, amiloride-containing Ringers solution and by subsequent superfusion with the same solution plus 10 µmol/L isoproterenol were consistent with both an acute and a sustained change in chloride transport in response to Moli1901. A similar analysis of NPD in the four CF participants demonstrated an acute response that resolved more quieldy. A dose-response relationship to Moli1901 was observed in non-CF participants, but a greater range of variability within the CF participants contributed to the lack of a clear dose-response relationship in this group. Conclusion: Moli1901 stimulates chloride transport in normal and CF nasal epithelia in vivo, but may have a shorter duration of action in CF participants. Key words: calcium; chloride transport; nasal potential difference; peptide. [ABSTRACT FROM AUTHOR]

Background: Nasal potential difference (PD) measurement quantifies the abnormal sodium and chloride transport that is characteristic of cystic fibrosis (CF) and has gained acceptance as both a diagnostic tool and outcome measure for new CF therapies. Because small changes in nasal PD-measured chloride transport are often an important component in evaluating new CF therapies, techniques to maximize sensitivity and reproducibility are essential. Study objective: To determine if administration of warmed nasal PD solutions (37°C), instead of room temperature solutions (22°C), results in significant increase in nasal PD-measured transepithelial chloride transport. Design: Multicenter, prospective, cross-over trial of repeated measurements of nasal PD at 22°C and 37°C. Results: Thirty-two healthy volunteers completed the study (four centers, each with 8 subjects). For 22°C vs 37°C, baseline (± SD) nasal PD (- 19.3 ± 6.9 millivolts [mV] vs - 18.8 ± 7.7 mV, p = 0.76), amiloride-sensitive PD (APD, 10.4 ± 5.6 mV vs 11.0 ± 6.1 reV, p = 0.60), and low chloride response (ΔPD, -10.0 ± 8.0 mV vs -8.0 ± 7.1 mV, p = 0.13) were not statistically significantly affected by wanning of solutions. Warming solutions to 37°C dramatically increased the chloride transport response to isoproterenol (APD, -6.9 ± 6.4 mV vs -13.3 ± 8.8 mV, p < 0.01) and the combined total response to low chloride and isoproterenol (APD, -16.9 ± 9.5 mV vs -21.3 ± 11.9 mV, p = 0.01). The average increases observed with warming in isoproterenol and combined total responses were -6.4 mV (95% confidence interval [CI], -8.5 to -4.3) and -4.4 mV (95% CI, -7.6 to -1.1), respectively. Conclusions: Performing nasal PD studies with solutions at 37°C instead of 22°C increases the observed total chloride response by approximately 25% and the isoproterenol-dependent chloride response by approximately 95%. The Cystic Fibrosis Foundation Therapeutics Development Network now recommends warming of solutions as a standard procedure for nasal PD protocols. Utilization of warmed solutions will standardize nasal PD techniques across centers and potentially increase the ability to identify therapies that result in small incremental improvements in CF transmembrane conductance regulator function. [ABSTRACT FROM AUTHOR]

Reports on drug developments for the treatment of cystic fibrosis. Delivery of therapeutic agents by aerosolization; Protection of lung function through the daily inhalation of a mucolytic agent; Improvement in efficacy and speed of delivery of inhaled medications.

We report two cases of acute pancreatitis secondary to minocycline use in adults with cystic fibrosis (CF). This minocycline complication has not previously been reported. Given the increased use of minocyline in the adult CF population to treat resistant bacteria, awareness of this potential adverse effect is imperative. As both of these individuals with CF had class IV genotypes and pancreatic sufficiency, close observation is warranted in the future to determine if persons with pancreatic-sufficient CF are at an increased risk for minocycline-induced pancreatitis. [ABSTRACT FROM AUTHOR]

Presents a letter to the editor of "CHEST" journal expressing appreciation of a January 2003 review by M. Gilljam and associates on gastrointestinal complications after lung transplantation in patients with cystic fibrosis.

The article reports on the connection between lung function, depression, and health-related quality of life (HRQoL) among adults with cystic fibrosis (CF). It is posed that more than 40 percent of people born with CF now reached adulthood. In this study, the Beck Depression Inventory and the Cystic Fibrosis Questionnaire were employed to assess depressive symptoms and the HRQoL of 76 adults who were taken as subjects of the research.

The article discusses a study which examined the appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis (CF). The study involved 216 patients with CF who were treated with vitamin D2. It was discovered that inadequate serum 25OHD levels are common in adults with CF and are associated with elevated parathyroid hormone (PTH) levels.

Background: The peptide drug Moli1901 activates an alternative chloride channel that is present in cystic fibrosis (CF) nasal and airway epithelia. Doing so bypasses the dysfunctional CF transmembrane regulator.Study Objective: To determine whether intranasal Moli1901 is safe, tolerable, and will induce chloride transport in healthy volunteers and CF subjects.Design: A single-blind (to the participant), randomized, placebo-controlled, dose-escalation study of intranasal Moli1901 was performed in four healthy non-CF participants and four participants with CF. Drug or placebo was administered by intranasal superfusion, and nasal potential difference responses were continuously monitored during sequential dose escalations at 1-min intervals from 0.01 through 10 micro mol/L.Results: Neither Moli1901 nor placebo were associated with visible changes such as edema, erythema, drainage, secretions, or ulcer formation. No elevations in lactate dehydrogenase, albumin, or cell counts were observed in nasal lavage fluid after administration. No clinically significant changes in FEV(1) or other toxicity parameters occurred. Changes in the nasal potential difference (NPD) induced by chloride-free, amiloride-containing Ringers solution and by subsequent superfusion with the same solution plus 10 micro mol/L isoproterenol were consistent with both an acute and a sustained change in chloride transport in response to Moli1901. A similar analysis of NPD in the four CF participants demonstrated an acute response that resolved more quickly. A dose-response relationship to Moli1901 was observed in non-CF participants, but a greater range of variability within the CF participants contributed to the lack of a clear dose-response relationship in this group.Conclusion: Moli1901 stimulates chloride transport in normal and CF nasal epithelia in vivo, but may have a shorter duration of action in CF participants. [ABSTRACT FROM AUTHOR]